Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 8/20 | 0.56 |
| ▸ | NPC1 | O15118 | 7/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | FDPS | P14324 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2837501 | 0.79 | ACP1 (0.65) | ACP1RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL27791809 | 0.77 | ACP1 (0.63) | ACP1RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL8868477 | 0.77 | ACP1 (0.63) | ACP1RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL479906 | 0.77 | ACP1 (0.63) | ACP1RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL1358344 | 0.77 | ACP1 (0.63) | ACP1RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL175217 | 0.77 | ADORA2A (0.68) | ACP1RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL3076122 | 0.77 | ACP1 (0.63) | ACP1RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL15480444 | 0.77 | ALDH1A1 (0.68) | ACP1RAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL8831598 | 0.77 | ACP1 (0.48) | ACP1RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL6374561 | 0.77 | ACP1 (0.58) | ACP1RAB9ANPC1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100595204-C | Bisaminated phosphonate prodrugs | METABASIS THERAPEUTICS INC | 2010-03-24 | — | — | CN | disclosed |
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | JIANG TAO | 2009-07-30 | — | — | US | disclosed |
| CN-101125864-A | Heteroaromatic inhibitor for fructose-1,6-bisphosphatase | METABASIS THERAPEUTICS INC (US) | 2008-02-20 | — | — | CN | disclosed |
| US-20080015195-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080004226-A1 | Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes | METABASIS THERAPEUTICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-7312219-B2 | Heteroaromatic inhibitors of fructose 1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| CN-100349904-C | Novel heteroaromatic inhibitors of fructose-1, 6-bisphosphatase | METABASIS THERAPEUTICS INC (US) | 2007-11-21 | — | — | CN | disclosed |
| US-20070232571-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| CN-1900087-A | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase | METABASIS THERAPEUTICS INC (US) | 2007-01-24 | — | — | CN | disclosed |
| CN-1704423-A | Novel heteroaromatic inhibitors of fructose-1, 6-bisphosphatase | METABASIS THERAPEUTICS INC (US) | 2005-12-07 | — | — | CN | disclosed |
| US-20040167178-A1 | Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes | ERION MARK D (US) | 2004-08-26 | — | — | US | disclosed |
| US-6756360-B1 | PHOSPHONATE, PHOSPHATE AND BISAMINO PHOSPHONATE DERIVATIVES | METABASIS THERAPEUTICS, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20040058892-A1 | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase | DANG QUN (US) | 2004-03-25 | — | — | US | disclosed |
| EP-1112275-B9 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS INC (US) | 2004-03-10 | — | — | EP | disclosed |
| EP-1112275-B1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS INC (US) | 2003-07-30 | — | — | EP | disclosed |
| US-6489476-B1 | FRUCTOSE-1,6-BISPHOSPHATASE ENZYME INHIBITORS ARE USEFUL IN THE TREATMENT OF DIABETES AND OTHER CONDITIONS ASSOCIATED WITH ELEVATED BLOOD GLUCOSE OR EXCESS GLYCOGEN STORAGE. | METABASIS THERAPEUTICS, INC. | 2002-12-03 | — | — | US | disclosed |
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | METABASIS THERAPEUTICS, INC. | 2002-11-21 | — | — | US | disclosed |
| EP-1143955-A3 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| EP-1143955-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000038666-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058892-A1 | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase | FBP1, G6PC1, HK1 | ACP1 726/4885RAB9A 3842/4885NPC1 1974/4885 |
| US-20080015195-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | FBP1, ALDOA, G6PC1 | ACP1 1068/4885RAB9A 3647/4885NPC1 1907/4885 |
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | FBP1, PFKFB1, G6PC1 | ACP1 388/4885RAB9A 1895/4885NPC1 1604/4885 |
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | FBP1, PFKFB1, PFKFB2 | ACP1 522/4885RAB9A 1770/4885NPC1 2241/4885 |
| US-20040167178-A1 | Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes | FBP1, G6PC1, IRS1 | ACP1 1167/4885RAB9A 4022/4885NPC1 2827/4885 |
| US-20070232571-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | FBP1, ALDOA, G6PC1 | ACP1 1068/4885RAB9A 3647/4885NPC1 1907/4885 |
| US-20080004226-A1 | Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes | FBP1, G6PC1, IRS1 | ACP1 1167/4885RAB9A 4022/4885NPC1 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.